The Lilly glucagon-like peptide-1 receptor (GLP-1R) agonist ( LSN3318839 ) is a positive allosteric modulator intended to treat type 2 diabetes. This drug candidate has an interesting proposed mechanism as a molecular glue between GLP-1R and GLP peptide, enhancing endogenous peptide activity. GLP-1 agonism is a well-established mechanism for [...]
< 1 minute read
Feb. 9, 2022
LSN3318839: a GLP-1R GLP Glue with Positive Allosteric Modulation
Lilly GLP Molecular Glue
GLP-1R/GLP molecular glue agonist (PAM) oral blood glucose↓, additive w/ sitaglipin from 220k cmpd cell-based screen + PK opt. LSN3318839 Lilly Research Laboratories, Indianapolis, IN